Cardioprotection for Duchenne's muscular dystrophy

American Heart Journal

Volumn 137, Issue 5, 1999, Pages 895-902

  Ishikawa, Yuka ^a   Bach, John R ^b   Minami, Ryoji ^b  

^a National Yakumo Hospital   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL; NORADRENALIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DRUG MIXTURE; DUCHENNE MUSCULAR DYSTROPHY; HEART DILATATION; HEART HEMODYNAMICS; HEART PROTECTION; HUMAN; MORTALITY; NEUROENDOCRINE SYSTEM; PATIENT MONITORING; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 0032908603     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70414-X     Document Type: Article

References (51)

1. 1. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Florence J, et al. Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurol 1989;39:475-81.
2. 2. Bach JR. Conventional approaches to managing neuromuscular ventilatory failure. In: Bach JR, editor. Pulmonary rehabilitation: the obstructive and paralytic conditions. Philadelphia: Hanley & Belfus; 1996:285-301.
3. 3. Rideau Y, Gatin G, Bach J, Gines G. Prolongation of life in Duchenne muscular dystrophy. Acta Neurol [Napoli] 1983;5:118-24.
4. 4. Nigro G, Comi L, Limongelli F, et al. Prospective study of X-linked progressive muscular dystrophy in Campania. Muscle Nerve 1983;1983;6:253-62.
5. 5. Hilton T, Orr RD, Perkin RM, Ashwal S. End of life care in Duchenne muscular dystrophy. Pediatr Neurol 1993;9:165-77.
6. 6. Ishikawa Y, Bach JR, Sarma RJ, Tamura T, Song J, Marra SW, et al. Cardiovascular considerations in the management of neuromuscular disease. Semin Neurol 1995;15:93-108.
7. 7. Bach JR. Update and perspectives on noninvasive respiratory muscle aids: part 1-the inspiratory muscle aids. Chest 1994;105:1230-40.
8. 8. Bach JR. Update and perspectives on noninvasive respiratory muscle aids: part 2-the expiratory muscle aids. Chest 1994;105:1538-44.
9. 9. Bach JR, Ishikawa Y, Kim H. Prevention of pulmonary morbidity for patients with Duchenne muscular dystrophy. Chest 1997;112: 1024-8.
10. 10. Tamura T, Shibuya N, Hashiba K, Oku Y, Mori H, Yano K. Evaluation of myocardial damage in Duchenne's muscular dystrophy with thallium201 myocardial SPECT [in Japanese]. Jpn Heart J 1993;34:51-61.
11. 11. Steward CA, Gilgoff I, Baydur A, Prentice W, Applebaum D. Gated radionuclide ventriculography in the evaluation of cardiac function in Duchenne's muscular dystrophy. Chest 1988;94:1245-8.
12. 12. Kashiwagi S, Akaike M, Kawai H, Adachi K, Saito S. Estimation of cardiac function by plasma concentration of brain natriuretic peptide in patients with Duchenne muscular dystrophy [in Japanese]. Clin Neurol (Tokyo) 1996;36:7-11.
13. 13. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
14. 14. Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, Mukoyama M, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993;87:464-9.
15. 15. Yamada Y, Goto J, Yokota M. Brain natriuretic peptide is a sensitive indicator of impaired left-ventricular function in elderly patients with cardiovascular disease. Cardiology 1997;88:401-7.
16. 16. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994;343:440-4.
17. 17. Kawai H, Adachi K, Kimura C, Nishiuchi T, Yamasaki Y, Tsutsui Y, et al. Secretion and clinical significance of atrial natriuretic peptide in patients with muscular dystrophy. Arch Neurol 1990; 47:900-4.
18. 18. Steinfath M, LavickyJ, Schmitz W, Schulz H, Daring V, Kalmar P. Changes in cardiac beta adrenoceptors in human heart diseases: relationship to the degree of heart failure and further evidence for etiology-related regulation of beta 1 and beta 2 subtypes. J Cardiothor Vasc Anesth 1993;7:668-73.
19. 19. Cooperative North Scandinavian Enalapril Survival Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-35.
20. 20. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997;30:27-34.
21. 21. Yoshikawa T, Handa S, Anzai T, Nishimura H, Baba A, Akaishi M, et al. Early reduction of neurohumoral factors plays a key role in mediating the efficacy of β-blocker therapy for congestive heart failure. Am Heart J 1996;131:329-36.
22. 22. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al for the Metoprolol in Dilated Cardiomyopathy (MDC) trial study group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6.
23. 23. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased beta receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 1989;79:483-90.
24. 24. Haber HL, Simek CL, Gimple LW, Bergin JD, Subbiah K, Jayaweera AR, et al. Why do patients with congestive heart failure tolerate the initiation of beta blocker therapy? Circulation 1993;88:1610-9.
25. 25. Di Lenardo A, Secoli G, Perkan A, Gregori D, Lardieri G, Pinamonti B, et al and the Heart Muscle Disease Study Group. Changing mortality in dilated cardiomyopathy. Br Heart J 1994; 72:S46-S51.
26. 26. Tamura T, Shibuya N, Iida M, Ishihara T, Fukunaga H. Kang J. Clinical evaluation of captopril in chronic cardiac dysfunction in patients with Duchenne muscular dystrophy [in Japanese]. Rinsho Iyaku (Jpn) 1996;12:3635-46.
27. 27. Gottlieb SS, Kukin ML, Ahern D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 1989;13:1534-9.
28. 28. Kawai H, Adachi K, Kimura C, Nishiuti T, Yamasaki Y, Tsutsui Y, et al. Secretion and clinical significance of atrial natriuretic peptide in patients with muscular dystrophy. Arch Neurol 1990;47:900-4.
29. 29. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. J Clin Invest 1991;87:1402-12.
30. 30. Davidson NC, Naas AA, Hanson JK, Kennedy NSJ, Coutie WJ, Struthers AD. Comparison of atrial atriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol 1996;77:828-31.
31. 31. Cohn JN, Levine B, Olivari MT, Garverg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
32. 32. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT. Circulation 1993;87:40-8.
33. 33. Nagasawa H, Nakajima T, Arakaki Y, Kamiya T. Normalization of left ventricular dimension in normal children by two-dimensional echocardiogram [in Japanese]. J Jpn Pediatr Soc 1994;98:1857-61.
34. 34. Towbin JA, Hejtmancik F, Brink P, Gelb B, Zhu XM, Chamberlain JS, et al. X-linked dilated cardiomyopathy: molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation 1993;87:1854-05.
35. 35. Kasper EK, Agema WRP, Hutchins GM, Deckers JW, Hare JM, Baughman KL. The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients. J Am Coll Cardiol 1994;23:586-90.
36. 36. Swedberg K. Effects of ACE-inhibition on renal function in severe congestive heart failure [in German]. Z Kardiol 1991;80:50-4.
37. 37. Cleland JGF, Dargie HJ, Mcalpine H, Ball SG, Morton JJ, Robertson JIS, et al. Severe hypotension after first dose of enalapril in heart failure. Br Med J 1985;291:1309-12.
38. 38. Dietz R, Nagel F, Osteziel KJ. Angiotensin-converting enzyme inhibitors and renal function in heart failure. Am J Cardiol 1992;70:119C-25C.
39. 39. Miyai I, Kang J, Nozaki S, Matsumura T. Alteration of atrial natriuretic peptide in progressive muscular dystrophy with congestive heart failure. Clin Neurol 1992;32:588-92.
40. 40. Riggs T, Oak R. Cardiomyopathy and pulmonary emboli in terminal Duchenne's muscular dystrophy. Am Heart J 1990;119:690-3.
41. 41. Ishihara Y, Tamura T, Nishimura T, Kawamura J, Kawashiro T. Prognosis of chronic left ventricular dysfunction in Duchenne muscular dystrophy. In: Annual report of the research on Nervous and Mental Disorders 1997, Tokyo, National Center of Neurology and Psychiatry 1997, p. 92.
42. 42. Takenaka A, Yokota M, Iwase M, Miyaguchi K,Hayashi H, Saito H. Discrepancy between systolic and diastolic dysfunction of the left ventricle in patients with Duchenne muscular dystrophy. Eur Heart J 1993;14:669-76.
43. 43. Danilowicz D, Rutkowski M, Myung D, Schively D. Echocardiography in Duchenne muscular dystrophy. Muscle Nerve 1980;3:298-303.
44. 44. Stewart CA, Gilgoff I, Baydur A, Prentice W, Applebaum D. Gated radionuclide ventriculography in the evaluation of cardiac function in Duchenne's muscular dystrophy. Chest 1988;94:1245-8.
45. 45. Yamamoto S, Matsushima H, Suzuki A, Sotobata I, Indo T, Matsuoka Y. A comparative study of thallium-201 single-photon emission computed tomography and electrocardiography in Duchenne and other types of muscular dystrophy. Am J Cardiol 1988;61:836-43.
46. 46. Grantham JA, Burnett JC. BNP: increasing importance in the pathophysiology and diagnosis of congestive heart failure. Circulation 1997;96:388-90.
47. 47. Cowie RM, Struthers AD, Wood DA, Coats AJS, Thompson SG, Poole-Wilson PA, et al. Value of natriuretic peptides in assessment of patients with passible new heart failure in primary care. Lancet 1997;350:1347-51.
48. 48. Andersson B, Blomstrom-Lundqvist C, Hedner T, Waagstein F. Exercise hemodynamics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failure. J Am Coll Cardiol 1991;1059-66.
49. 49. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Levy D. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med 1997;336:1350-5.
50. 50. Honda M. Sequential observations of the cardiac function in patients with Duchenne's progressive muscular dystrophy: comparative studies of surviving and dying patients [in Japanese]. Chiba Univ Med J 1985;61:187-97.
51. 51. Miyatani N, Yazawa Y, Harayama H, Tokiguchi S, Yuasa T. Case report of young boy with Duchenne muscular dystrophy with congestive heart failure [in Japanese]. Neurology (Tokyo) 1981;15:590-2.